// App-Quantinova.ai

339 : The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).

Researchers

Presenter

  • Andrew Lachlan Schmidt

Principal Investigators

  • Chun Loo Gan

  • Connor Wells

  • Shaan Dudani

  • Frede Donskov

  • Camillo Porta

  • Cristina Suarez

  • Bernadett Szabados

  • Lori Wood

  • Jose Manuel Ruiz Morales

  • Ben Tran

  • Georg A. Bjarnason

  • Takeshi Yuasa

  • Benoit Beuselinck

  • Aaron Richard Hansen

  • Neeraj Agarwal

  • Ziad Bakouny

  • Daniel Yick Chin Heng

  • Toni K. Choueiri

Medical Centers

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Queen's University, Kingston, ON, CA

  • Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada

  • Aarhus University Hospital, Aarhus, Denmark

  • Department of Internal Medicine, University of Pavia and Division of Traslational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy

  • Vall dHebron University Hospital and Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain

  • Bart's Cancer Institute, London, United Kingdom

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Hospital Medica Sur, Mexico City, Mexico

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Sunnybrook Research Institute, Toronto, ON, Canada

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Leuven Cancer Institute, Universitaire Ziekenhuizen, Leuven, Belgium

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

  • Canada

  • Denmark

  • Italy

  • Spain

  • United Kingdom

  • Mexico

  • Australia

  • Japan

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved